# Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

> **NCT03874494** · PHASE3 · COMPLETED · sponsor: **Otsuka Beijing Research Institute** · enrollment: 371 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Brexpiprazole
- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT03874494
- **Lead sponsor:** Otsuka Beijing Research Institute
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-27
- **Primary completion:** 2021-08-06
- **Final completion:** 2021-09-06
- **Target enrollment:** 371 (ACTUAL)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03874494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03874494, "Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03874494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*